Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
about
Can follicular helper T cells be targeted to improve vaccine efficacy?Recent update in HIV vaccine developmentThe evolution within usRecent strategies targeting HIV glycans in vaccine designStructural insights on the role of antibodies in HIV-1 vaccine and therapyAntibody responses to envelope glycoproteins in HIV-1 infectionHIV-1 neutralizing antibodies: understanding nature's pathwaysNeutralization-Enhancing RF Antibodies for HIV VaccinesAntibodies in HIV-1 vaccine development and therapyDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionCatching HIV 'in the act' with 3D electron microscopyHuman Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesVaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteHIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunizationStructural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsCo-evolution of a broadly neutralizing HIV-1 antibody and founder virusDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodiesVaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A VirusesStructures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designOptimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based DesignA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionBroadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding GlycansRabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected HumansMultidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class AntibodiesThe Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV AntibodiesStructural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 EpitopeStructural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorDelineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralizationSomatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing AntibodiesHigh-Throughput Sequencing-Based Immune Repertoire Study during Infectious DiseaseComputational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity dataWhat Are the Most Powerful Immunogen Design Vaccine Strategies?Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral InhibitionHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Recent Insights into the HIV/AIDS Pandemic.Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.
P2860
Q26753848-6F5B7ED0-A1D8-406F-B625-38FED9EA9AEEQ26766628-6060E4A1-9376-46FB-8395-3C3ABDB282F4Q26801603-EF443285-94BE-4F0D-93F7-8BC1C87A1753Q26823603-EBA349DF-D367-4BAF-BB77-1E3EE8487981Q26829461-08FB1436-58F7-44B0-B018-6E87A1D96F51Q26991572-B2C734F4-B4AB-4137-92C3-89B51A1CC8B8Q27000480-A06EC9C0-24E1-49D4-A6AB-9013C3FFCA60Q27002322-657C1001-86AE-4843-BABE-28BF84AD3620Q27011574-C502B2A4-ABBE-4798-8238-6F0829697BCEQ27022652-3CE35E73-8E53-4D0D-9987-6024DB7A5C47Q27026806-551141A1-4016-4215-A462-4468775326AFQ27318508-4A7AB57F-37B0-4F1F-864A-DB737BACCA5EQ27319450-440D1253-43EA-42B9-A599-F1DE7C24472EQ27324184-33CF4BBA-B5A1-4520-8703-4A723230B16CQ27643993-F55B498F-BDE6-41CE-9D1B-A497F0E2D814Q27644501-CA3DE692-2BFD-4343-A559-EB687EE776B4Q27644515-18EE1B73-118D-4673-B36B-C6636B1E624CQ27644544-77FF98C0-D029-4127-8EDD-F96680B78DE8Q27644634-D7B30C3F-292D-4553-ABCE-04495A7BD09AQ27644646-C482FE23-3E11-4695-ADB3-698B49E816CBQ27676864-ABAC73B7-2298-43D1-BC8F-57800597ABE8Q27678062-436B2ECA-29CE-4126-965D-083299AFE70BQ27679123-547A1DFF-A375-42E6-9FD9-A0DD9D55E471Q27679353-23B28EB1-7CDF-4D06-A2D3-42FB53C75487Q27680688-A32BEE08-E078-4CFB-B990-51787A715485Q27680810-887E3409-B1AD-4743-9400-655114B725BDQ27680872-69CC22E9-E2FF-40E0-962C-B455AC5C2506Q27681352-E98C7D85-1ACC-4FBF-B871-4B06B163051BQ27683553-06348735-7B80-41B4-9C9B-F29D1C5ADE87Q27684529-08896054-7D89-4D45-B855-71A7FB847ED2Q27684578-3BA3CFF2-8A50-4122-A4B9-17B6D5400E8AQ27723297-5696411B-8170-40B7-A0E1-EB1072B080AAQ28068214-2658B19F-F3A3-42AC-BC90-F213CD985348Q28535583-9A9A0C4C-085A-430B-A321-F072D841A352Q28729792-7BAE380A-3912-48BE-96DC-F8670AC165B3Q28831255-05CFC22A-4981-4E81-A36D-53CC30A42D64Q30234773-1107D405-C1DD-42D8-963C-DF99E8E1DF26Q30235024-CD7E985C-F91D-4F79-A29C-B0AC2A874809Q30353580-05F0C260-7AB8-418E-A9C4-D92A1066F223Q30353709-A03224BF-7CC7-412F-BA1E-9A8E66213591
P2860
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@ast
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@en
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@nl
type
label
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@ast
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@en
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@nl
prefLabel
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@ast
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@en
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@nl
P2860
P921
P3181
P1433
P1476
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
@en
P2093
Peter D Kwong
P2860
P304
P3181
P356
10.1016/J.IMMUNI.2012.08.012
P407
P577
2012-09-21T00:00:00Z